United States Patent 7,951,133: Scope, Claim Architecture, and US Landscape
US Patent 7,951,133 claims a procedural method for treating a sinus condition using a biodegradable, solid implant delivered into a paranasal sinus cavity, where the implant has two delivery/positioning forms (a first delivery form and a second shape that “substantially prevents clearance”), and where the implant contains a therapeutic amount of an active agent. The claim set also pins down multiple delivery modes (ostium delivery, sinus wall delivery, pusher, pressurized gas, and conduit geometries) and multiple active agents (specifically anti-inflammatory corticosteroids).
What does the independent claim actually cover?
Claim 1 (independent) scope
Claim 1 is a method claim with these required elements:
| Element |
Claim language (core limitation) |
Practical meaning for coverage |
| Treatment target |
“treating a sinus condition” |
Broad sinus indication coverage at the method level (no specific disease term recited) |
| Access |
“creating access to a paranasal sinus cavity” with a delivery device loaded with a biodegradable implant |
Requires an access step and a device loaded with implant |
| Delivery step |
“delivering the biodegradable implant to the paranasal sinus cavity” |
Active delivery into the sinus cavity is mandatory |
| Implant type |
“biodegradable implant… solid implant” |
Implant is solid (not a liquid/gas) and is biodegradable |
| Two-form implant |
“first delivery form… and a second form, different from the first… second form having a shape that substantially prevents clearance” |
The implant must change from a first form to a second, in-situ geometry designed to resist expulsion/clearance |
| Therapeutic payload |
“biodegradable implant comprises a therapeutic amount of an active agent” |
Any active agent can fit, but dependent claims narrow to anti-inflammatories |
Key coverage implication: A competitor can avoid the patent only by breaking at least one hard element in Claim 1: (i) biodegradable solid implant with a two-form delivery/positioning shape; (ii) delivery into a paranasal sinus cavity; (iii) therapeutic amount of an active agent in the implant; or (iv) the “second form” being shaped to prevent clearance.
How do dependent claims narrow the method?
Delivery route and delivery mechanics
Claims 2–5 specify routes and delivery mechanics:
| Claim |
Added limitation |
Scope effect |
| 2 |
Delivery “through a sinus ostium” |
Limits method to natural ostium route |
| 3 |
Delivery “through a sinus wall” |
Alternative route for delivery |
| 4 |
Delivery “with a pusher” |
Narrows delivery actuator |
| 5 |
Delivery “with a pressurized gas” |
Narrows delivery actuator to gas-assisted delivery |
Device geometry
Claims 7–11 constrain the delivery device:
| Claim |
Added limitation |
Scope effect |
| 6 |
“biodegradable polymeric implant” |
Narrows material class to biodegradable polymer |
| 7 |
“sharp-tipped conduit” |
Specific device end |
| 8 |
“angulated conduit” |
Specific device curvature |
| 9 |
“distal portion… angulated… about zero degrees to about 135 degrees” |
Gives numeric angle range for conduit distal angulation |
| 10 |
Distal opening “located at the tip” |
Outlet configuration |
| 11 |
Distal opening “located in a side wall” |
Outlet configuration |
Coverage implication: These dependent claims create multiple “fallbacks.” A product that uses gas-assisted delivery but with different conduit geometry might still avoid some dependents but remain within Claim 1 if Claim 1’s core two-form implant and delivery into a sinus cavity are met.
Implant structural and payload narrowing
Claims 12 and 13–17 narrow the implant structure and active agent:
| Claim |
Added limitation |
Scope effect |
| 12 |
Implant has “a series of predetermined fracture lines” |
Narrows implant design to fracture-line mechanics (likely related to controlled fragmentation as it biodegrades) |
| 13 |
Active agent is an “anti-inflammatory active agent” |
Narrows payload class |
| 14–17 |
Anti-inflammatory agent is specifically mometasone furoate, budesonide, fluticasone propionate, triamcinolone acetonide |
Narrows payload to named corticosteroids |
Coverage implication: The independent claim is broad on “active agent,” but the dependent set explicitly targets common intranasal steroid molecules. Competitors using those molecules in a biodegradable solid implant delivered into a sinus cavity with a two-form clearance-resistant shape are pulled directly into the narrower claim corridor.
How to map Claim 1 to product design around it
Core “design-around” fault lines
A method competitor has to disrupt at least one required Claim 1 feature:
- Two-form implant with clearance-preventing second form
- If the implant does not have a first delivery form and a second different form with a geometry that “substantially prevents clearance,” Claim 1 is harder to satisfy.
- Solid biodegradable implant
- A non-solid delivery system (or non-biodegradable) would miss the claim’s implant definition.
- Therapeutic active agent contained in the biodegradable implant
- If therapy is delivered without drug being part of the biodegradable solid implant, Claim 1 is potentially avoidable.
- Delivery into a paranasal sinus cavity with access
- A different anatomical target or a procedure that does not create access and deliver a loaded biodegradable implant into the paranasal cavity could avoid the method.
Less decisive features (dependent claim territory)
The following features mainly determine whether a competitor falls into dependent claims, not whether Claim 1 applies:
- Ostium vs sinus wall delivery (Claims 2–3)
- Pusher vs pressurized gas (Claims 4–5)
- Sharp-tipped or angulated conduits and numeric angles (Claims 7–9)
- Distal opening at tip vs side wall (Claims 10–11)
- Fracture lines (Claim 12)
- Specific steroid molecules (Claims 14–17)
Key claim construction pressure points (where litigation usually concentrates)
“Second form” and “substantially prevents clearance”
Claim 1 hinges on a shape change from a first delivery form to a second in-situ form that prevents clearance. This creates two claim construction battles:
- What counts as “different” forms? The implant must be in a delivery geometry that transitions to another geometry once inside the sinus.
- How “substantially prevents clearance” is quantified? The claim does not provide a numeric threshold, so practice-based metrics (retention time, expulsion rates) would matter for both claim interpretation and infringement.
“Solid implant” vs polymeric form
The claim requires a solid implant; Claim 6 further specifies biodegradable polymeric implant. If a system is partially soft or gel-like during placement, a defendant would try to argue it is not a “solid implant” or not “biodegradable” in the required way.
“Therapeutic amount”
The claim does not define dosage boundaries. In disputes, the question becomes whether the formulation and dose inside the implant is a therapeutic amount for the claimed sinus condition.
Patent landscape: where this claim sits and what it likely overlaps
The provided material includes only the claim text. Without the complete specification, file history, and cited references, a precise citation-backed landscape cannot be produced here. Under those constraints, the only actionable “landscape” analysis that can be stated is the topical adjacency implied by the claim itself, which maps to a recognizable technology cluster:
Technology cluster suggested by the claims
- Biodegradable sinus implants designed for in-sinus placement
- Drug-eluting or drug-loaded biodegradable polymers for sinus inflammatory conditions
- Corticosteroid payloads including mometasone furoate, budesonide, fluticasone propionate, triamcinolone acetonide
- Delivery devices using conduits, angulated tips, and outlet configurations; delivery via sinus ostium or sinus wall; delivery using pusher or pressurized gas
- Retention/anti-clearance mechanisms via a changed second-form geometry
- Controlled fragmentation via predetermined fracture lines
Where overlaps commonly occur
In this space, overlaps generally arise among:
- Implant form factor patents (how the implant occupies the cavity and resists expulsion)
- Drug selection and drug loading patents (steroid molecules and dosing concepts)
- Delivery device patents (conduit geometry, actuator type, placement route)
- Procedural patents (access and placement steps for sinus cavities)
Business implication: Claim 1’s combination of (i) biodegradable solid implant with (ii) two-form clearance-resistant geometry and (iii) therapeutic active agent in a sinus cavity is the integration point. Patents that separately claim drug loading, delivery instruments, or implant geometry without the combined “two-form” retention behavior may not directly block Claim 1, but they may block subsystems or induce design-around constraints.
Freedom-to-operate (FTO) lens: what you’d clear vs what you’d still worry about
Most clearance-critical design features
- Use of a biodegradable solid implant (not a non-solid depot)
- A two-form mechanism (delivery form to second in-situ form)
- A second form that provides anti-clearance retention
- Implant containing a therapeutic amount of an active agent
- Delivery into a paranasal sinus cavity via creating access and using a delivery device loaded with implant
Secondary areas that still matter if you plan to change the delivery
- Ostium vs sinus wall placement
- Gas vs pusher actuation
- Conduit tip vs side outlet
- Angulation range
- Fracture line mechanics
- Whether the active agent is one of the enumerated corticosteroids
Key Takeaways
- US 7,951,133 is anchored by Claim 1: a method delivering a biodegradable solid implant into a paranasal sinus cavity, where the implant has first delivery form and a second different form that substantially prevents clearance, and the implant contains a therapeutic amount of an active agent.
- Dependent claims add multiple “fallback corridors” across delivery routes (ostium or sinus wall), actuation (pusher or pressurized gas), delivery device geometry (sharp tip, angulated conduit, outlet at tip or side wall, with an angulation range), implant structure (predetermined fracture lines), and active agents (anti-inflammatory corticosteroids including mometasone furoate, budesonide, fluticasone propionate, triamcinolone acetonide).
- The practical infringement/design-around hinge is the two-form anti-clearance implant geometry, followed by the biodegradable solid implant with a drug payload delivered into the sinus cavity.
FAQs
1. What is the single most important requirement in Claim 1?
The implant must have a second in-situ form different from the first delivery form, with a shape that substantially prevents clearance, and it must be a biodegradable solid implant loaded with a therapeutic active agent delivered into a paranasal sinus cavity.
2. Does the patent require a specific sinus disease term?
No. Claim 1 says “treating a sinus condition” without naming a specific diagnosis.
3. Can delivery be through a sinus ostium and still infringe?
Yes. Claim 2 requires ostium delivery as a dependent limitation; if a method satisfies Claim 1, using an ostium falls within Claim 2’s narrowed scope.
4. Do the named corticosteroids matter only if you use one of them?
Yes. Claims 14–17 narrow the anti-inflammatory agent to specific molecules. Using other anti-inflammatory actives can still fit Claim 13, but not Claims 14–17.
5. What happens if an implant lacks fracture lines?
That would avoid Claim 12, but it may still infringe the broader Claim 1 unless the missing fracture lines relate to satisfying the core elements.
References
[1] United States Patent No. 7,951,133 (claims provided in prompt).
